Publication Information

{'id': 'https://openalex.org/W1484597035', 'doi': 'https://doi.org/10.1158/1538-7445.am2014-5602', 'title': 'Abstract 5602: BRAF V600 mutated allelic specific imbalance (MASI) impact on sensitivity to vemurafenib', 'display_name': 'Abstract 5602: BRAF V600 mutated allelic specific imbalance (MASI) impact on sensitivity to vemurafenib', 'publication_year': 2014, 'publication_date': '2014-10-01', 'ids': {'openalex': 'https://openalex.org/W1484597035', 'doi': 'https://doi.org/10.1158/1538-7445.am2014-5602', 'mag': '1484597035'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2014-5602', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5057418532', 'display_name': 'Amélie Boespflug', 'orcid': 'https://orcid.org/0000-0002-2656-5144'}, 'institutions': [{'id': 'https://openalex.org/I4210100596', 'display_name': 'Hospices Civils de Lyon', 'ror': 'https://ror.org/01502ca60', 'country_code': 'FR', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210100596']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Amelie Boespflug', 'raw_affiliation_strings': ['1Hospices Civils de Lyon, Pierre Bénite, France;'], 'affiliations': [{'raw_affiliation_string': '1Hospices Civils de Lyon, Pierre Bénite, France;', 'institution_ids': ['https://openalex.org/I4210100596']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5081297649', 'display_name': 'L. Thomas', 'orcid': 'https://orcid.org/0000-0003-1995-2434'}, 'institutions': [{'id': 'https://openalex.org/I100532134', 'display_name': 'Université Claude Bernard Lyon 1', 'ror': 'https://ror.org/029brtt94', 'country_code': 'FR', 'type': 'education', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I203339264']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Luc Thomas', 'raw_affiliation_strings': ['2Lyon 1 University Hopitaux de Lyon, Pierre Bénite, France;'], 'affiliations': [{'raw_affiliation_string': '2Lyon 1 University Hopitaux de Lyon, Pierre Bénite, France;', 'institution_ids': ['https://openalex.org/I100532134']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5005476354', 'display_name': 'Pascal Rousset', 'orcid': 'https://orcid.org/0000-0001-6956-2800'}, 'institutions': [{'id': 'https://openalex.org/I4210100596', 'display_name': 'Hospices Civils de Lyon', 'ror': 'https://ror.org/01502ca60', 'country_code': 'FR', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210100596']}, {'id': 'https://openalex.org/I100532134', 'display_name': 'Université Claude Bernard Lyon 1', 'ror': 'https://ror.org/029brtt94', 'country_code': 'FR', 'type': 'education', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I203339264']}, {'id': 'https://openalex.org/I178906410', 'display_name': 'Lyon College', 'ror': 'https://ror.org/03c4kec23', 'country_code': 'US', 'type': 'education', 'lineage': ['https://openalex.org/I178906410']}], 'countries': ['FR', 'US'], 'is_corresponding': False, 'raw_author_name': 'Pascal Rousset', 'raw_affiliation_strings': ['3Lyon 1 University; Hopitaux Civils de Lyon, Lyon, France;', 'Lyon 1 University'], 'affiliations': [{'raw_affiliation_string': '3Lyon 1 University; Hopitaux Civils de Lyon, Lyon, France;', 'institution_ids': ['https://openalex.org/I4210100596', 'https://openalex.org/I100532134']}, {'raw_affiliation_string': 'Lyon 1 University', 'institution_ids': ['https://openalex.org/I178906410', 'https://openalex.org/I100532134']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5006793451', 'display_name': 'Charles Dumontet', 'orcid': 'https://orcid.org/0000-0003-1875-134X'}, 'institutions': [{'id': 'https://openalex.org/I4210125048', 'display_name': 'Centre de Recherche en Cancérologie de Lyon', 'ror': 'https://ror.org/02mgw3155', 'country_code': 'FR', 'type': 'facility', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I1294671590', 'https://openalex.org/I154526488', 'https://openalex.org/I203339264', 'https://openalex.org/I4210096427', 'https://openalex.org/I4210105738', 'https://openalex.org/I4210125048']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Charles Dumontet', 'raw_affiliation_strings': ['4Cancer Research Center of Lyon (CRCL), Lyon, France;'], 'affiliations': [{'raw_affiliation_string': '4Cancer Research Center of Lyon (CRCL), Lyon, France;', 'institution_ids': ['https://openalex.org/I4210125048']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5081121101', 'display_name': 'Julie Caramel', 'orcid': 'https://orcid.org/0000-0002-8883-918X'}, 'institutions': [{'id': 'https://openalex.org/I4210125048', 'display_name': 'Centre de Recherche en Cancérologie de Lyon', 'ror': 'https://ror.org/02mgw3155', 'country_code': 'FR', 'type': 'facility', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I1294671590', 'https://openalex.org/I154526488', 'https://openalex.org/I203339264', 'https://openalex.org/I4210096427', 'https://openalex.org/I4210105738', 'https://openalex.org/I4210125048']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Julie Caramel', 'raw_affiliation_strings': ['4Cancer Research Center of Lyon (CRCL), Lyon, France;'], 'affiliations': [{'raw_affiliation_string': '4Cancer Research Center of Lyon (CRCL), Lyon, France;', 'institution_ids': ['https://openalex.org/I4210125048']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5087261048', 'display_name': 'Carole Ferraro‐Peyret', 'orcid': 'https://orcid.org/0000-0002-4221-9698'}, 'institutions': [{'id': 'https://openalex.org/I4210125048', 'display_name': 'Centre de Recherche en Cancérologie de Lyon', 'ror': 'https://ror.org/02mgw3155', 'country_code': 'FR', 'type': 'facility', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I1294671590', 'https://openalex.org/I154526488', 'https://openalex.org/I203339264', 'https://openalex.org/I4210096427', 'https://openalex.org/I4210105738', 'https://openalex.org/I4210125048']}, {'id': 'https://openalex.org/I100532134', 'display_name': 'Université Claude Bernard Lyon 1', 'ror': 'https://ror.org/029brtt94', 'country_code': 'FR', 'type': 'education', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I203339264']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Carole Ferraro-Peyret', 'raw_affiliation_strings': ['5Hopitaux Civils de Lyon, Lyon 1 University, Cancer Research Center of Lyon, Lyon, France;'], 'affiliations': [{'raw_affiliation_string': '5Hopitaux Civils de Lyon, Lyon 1 University, Cancer Research Center of Lyon, Lyon, France;', 'institution_ids': ['https://openalex.org/I4210125048', 'https://openalex.org/I100532134']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5110269145', 'display_name': 'Pierre Paul Bringuier', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210100596', 'display_name': 'Hospices Civils de Lyon', 'ror': 'https://ror.org/01502ca60', 'country_code': 'FR', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210100596']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Pierre Paul Bringuier', 'raw_affiliation_strings': ['6Hospices Civils de Lyon, Lyon, France;'], 'affiliations': [{'raw_affiliation_string': '6Hospices Civils de Lyon, Lyon, France;', 'institution_ids': ['https://openalex.org/I4210100596']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5112766102', 'display_name': 'B. Balme', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210100596', 'display_name': 'Hospices Civils de Lyon', 'ror': 'https://ror.org/01502ca60', 'country_code': 'FR', 'type': 'healthcare', 'lineage': ['https://openalex.org/I4210100596']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Brigitte Balme', 'raw_affiliation_strings': ['1Hospices Civils de Lyon, Pierre Bénite, France;'], 'affiliations': [{'raw_affiliation_string': '1Hospices Civils de Lyon, Pierre Bénite, France;', 'institution_ids': ['https://openalex.org/I4210100596']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5073133195', 'display_name': 'Stéphane Dalle', 'orcid': 'https://orcid.org/0000-0002-3423-4548'}, 'institutions': [{'id': 'https://openalex.org/I4210125048', 'display_name': 'Centre de Recherche en Cancérologie de Lyon', 'ror': 'https://ror.org/02mgw3155', 'country_code': 'FR', 'type': 'facility', 'lineage': ['https://openalex.org/I100532134', 'https://openalex.org/I1294671590', 'https://openalex.org/I154526488', 'https://openalex.org/I203339264', 'https://openalex.org/I4210096427', 'https://openalex.org/I4210105738', 'https://openalex.org/I4210125048']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Stephane Dalle', 'raw_affiliation_strings': ['7Cancer Research Center of Lyon, Pierre Bénite, France.'], 'affiliations': [{'raw_affiliation_string': '7Cancer Research Center of Lyon, Pierre Bénite, France.', 'institution_ids': ['https://openalex.org/I4210125048']}]}], 'institution_assertions': [], 'countries_distinct_count': 2, 'institutions_distinct_count': 4, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 66}, 'biblio': {'volume': '74', 'issue': '19_Supplement', 'first_page': '5602', 'last_page': '5602'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11533', 'display_name': 'Melanoma and MAPK Pathways', 'score': 0.9986, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11533', 'display_name': 'Melanoma and MAPK Pathways', 'score': 0.9986, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T10274', 'display_name': 'Synthesis and biological activity', 'score': 0.9775, 'subfield': {'id': 'https://openalex.org/subfields/1605', 'display_name': 'Organic Chemistry'}, 'field': {'id': 'https://openalex.org/fields/16', 'display_name': 'Chemistry'}, 'domain': {'id': 'https://openalex.org/domains/3', 'display_name': 'Physical Sciences'}}, {'id': 'https://openalex.org/T10755', 'display_name': 'HER2/EGFR in Cancer Research', 'score': 0.9597, 'subfield': {'id': 'https://openalex.org/subfields/2730', 'display_name': 'Oncology'}, 'field': {'id': 'https://openalex.org/fields/27', 'display_name': 'Medicine'}, 'domain': {'id': 'https://openalex.org/domains/4', 'display_name': 'Health Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/dabrafenib', 'display_name': 'Dabrafenib', 'score': 0.896628}, {'id': 'https://openalex.org/keywords/trametinib', 'display_name': 'Trametinib', 'score': 0.632992}, {'id': 'https://openalex.org/keywords/v600e', 'display_name': 'V600E', 'score': 0.5573402}, {'id': 'https://openalex.org/keywords/compound-heterozygosity', 'display_name': 'Compound heterozygosity', 'score': 0.4441892}, {'id': 'https://openalex.org/keywords/heterozygote-advantage', 'display_name': 'Heterozygote advantage', 'score': 0.43820006}], 'concepts': [{'id': 'https://openalex.org/C2776131300', 'wikidata': 'https://www.wikidata.org/wiki/Q423111', 'display_name': 'Vemurafenib', 'level': 4, 'score': 0.96652985}, {'id': 'https://openalex.org/C2778830669', 'wikidata': 'https://www.wikidata.org/wiki/Q3011604', 'display_name': 'Dabrafenib', 'level': 5, 'score': 0.896628}, {'id': 'https://openalex.org/C2777658100', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Melanoma', 'level': 2, 'score': 0.7118634}, {'id': 'https://openalex.org/C502942594', 'wikidata': 'https://www.wikidata.org/wiki/Q3421914', 'display_name': 'Cancer research', 'level': 1, 'score': 0.67128605}, {'id': 'https://openalex.org/C2778472372', 'wikidata': 'https://www.wikidata.org/wiki/Q7833138', 'display_name': 'Trametinib', 'level': 4, 'score': 0.632992}, {'id': 'https://openalex.org/C207001950', 'wikidata': 'https://www.wikidata.org/wiki/Q141124', 'display_name': 'In vivo', 'level': 2, 'score': 0.6160429}, {'id': 'https://openalex.org/C71924100', 'wikidata': 'https://www.wikidata.org/wiki/Q11190', 'display_name': 'Medicine', 'level': 0, 'score': 0.5625598}, {'id': 'https://openalex.org/C2776470698', 'wikidata': 'https://www.wikidata.org/wiki/Q21851559', 'display_name': 'V600E', 'level': 4, 'score': 0.5573402}, {'id': 'https://openalex.org/C62112901', 'wikidata': 'https://www.wikidata.org/wiki/Q189159', 'display_name': 'Cell growth', 'level': 2, 'score': 0.53707886}, {'id': 'https://openalex.org/C81885089', 'wikidata': 'https://www.wikidata.org/wiki/Q189082', 'display_name': 'Cell culture', 'level': 2, 'score': 0.51399344}, {'id': 'https://openalex.org/C501734568', 'wikidata': 'https://www.wikidata.org/wiki/Q42918', 'display_name': 'Mutation', 'level': 3, 'score': 0.4938889}, {'id': 'https://openalex.org/C1491633281', 'wikidata': 'https://www.wikidata.org/wiki/Q7868', 'display_name': 'Cell', 'level': 2, 'score': 0.46359864}, {'id': 'https://openalex.org/C12125453', 'wikidata': 'https://www.wikidata.org/wiki/Q5156837', 'display_name': 'Compound heterozygosity', 'level': 4, 'score': 0.4441892}, {'id': 'https://openalex.org/C153471976', 'wikidata': 'https://www.wikidata.org/wiki/Q2873354', 'display_name': 'Heterozygote advantage', 'level': 4, 'score': 0.43820006}, {'id': 'https://openalex.org/C180754005', 'wikidata': 'https://www.wikidata.org/wiki/Q80726', 'display_name': 'Allele', 'level': 3, 'score': 0.4133444}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.36020195}, {'id': 'https://openalex.org/C203014093', 'wikidata': 'https://www.wikidata.org/wiki/Q101929', 'display_name': 'Immunology', 'level': 1, 'score': 0.3281473}, {'id': 'https://openalex.org/C54355233', 'wikidata': 'https://www.wikidata.org/wiki/Q7162', 'display_name': 'Genetics', 'level': 1, 'score': 0.16108066}, {'id': 'https://openalex.org/C2994587330', 'wikidata': 'https://www.wikidata.org/wiki/Q180614', 'display_name': 'Metastatic melanoma', 'level': 3, 'score': 0.14121619}, {'id': 'https://openalex.org/C104317684', 'wikidata': 'https://www.wikidata.org/wiki/Q7187', 'display_name': 'Gene', 'level': 2, 'score': 0.123363435}, {'id': 'https://openalex.org/C62478195', 'wikidata': 'https://www.wikidata.org/wiki/Q828130', 'display_name': 'Signal transduction', 'level': 2, 'score': 0.083260685}, {'id': 'https://openalex.org/C57074206', 'wikidata': 'https://www.wikidata.org/wiki/Q14197552', 'display_name': 'MAPK/ERK pathway', 'level': 3, 'score': 0.0686008}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1538-7445.am2014-5602', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S168522863', 'display_name': 'Cancer Research', 'issn_l': '0008-5472', 'issn': ['0008-5472', '1538-7445'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.78, 'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W4249533637', 'https://openalex.org/W4223510352', 'https://openalex.org/W3139482786', 'https://openalex.org/W2943666471', 'https://openalex.org/W2884253050', 'https://openalex.org/W2792819107', 'https://openalex.org/W2610300953', 'https://openalex.org/W2236199583', 'https://openalex.org/W2058633833', 'https://openalex.org/W2023835753'], 'abstract_inverted_index': {'Abstract': [0], 'V600': [1, 121, 155, 180, 286, 481], 'mutations': [2, 25, 156], 'of': [3, 9, 31, 64, 89, 146, 257, 324, 340, 380, 394, 421, 424, 433, 440, 443, 452, 495, 500], 'BRAF': [4, 32, 42, 68, 90, 120, 154, 179, 248, 285, 341, 370, 425, 453, 480], 'are': [5, 13, 26, 244], 'present': [6], 'in': [7, 116, 128, 140, 192, 220, 251, 254, 342, 354, 357, 372, 375, 448], '40%': [8], 'cutaneous': [10], 'melanoma': [11, 71, 93, 124, 151, 182, 343], 'and': [12, 44, 61, 86, 103, 110, 114, 131, 159, 210, 219, 268, 351, 356, 374, 390], 'currently': [14], 'targeted': [15], 'for': [16, 207, 215, 231, 238, 265, 274, 504], 'therapy': [17], 'by': [18], 'specific': [19, 35, 484], 'inhibitors': [20, 43, 249], '(vemurafenib,': [21], 'dabrafenib).': [22], 'While': [23], 'BRAFV600': [24], 'mostly': [27], 'heterozygous,': [28, 117], 'the': [29, 39, 81, 422, 444, 496, 501], 'impact': [30, 82, 487], 'mutated': [33, 70, 92, 122, 181, 287, 482], 'allelic': [34, 483], 'imbalance': [36, 485], '(MASI)': [37, 486], 'on': [38, 45, 83, 225, 388, 488], 'sensitivity': [40, 63, 111, 132, 489], 'to': [41, 106, 112, 133, 204, 213, 247, 262, 271, 312, 316, 369, 436, 455, 490], 'clinical': [46], 'outcome': [47], 'has': [48], 'not': [49], 'been': [50], 'evaluated': [51, 137, 387], 'so': [52], 'far.': [53], 'Here': [54], 'we': [55], 'compared': [56, 166], 'cell': [57, 72, 108, 125, 183, 190, 217, 242, 276, 349], 'proliferation,': [58], 'tumor': [59], 'growth': [60, 109], 'vemurafenib': [62, 113, 134, 258], 'heterozygous': [65, 178, 216, 239, 275], 'versus': [66, 118, 305, 328], 'homozygous': [67, 119, 189, 232, 266], 'V600E': [69, 91], 'lines.': [73, 126], 'We': [74, 100, 278], 'also': [75, 136, 280, 363], 'performed': [76], 'a': [77, 153, 294, 338, 347, 366, 401, 404, 430], 'retrospective': [78, 144], 'study': [79, 335, 420], 'evaluating': [80], 'overall': [84, 298], 'survival': [85, 299], 'drug': [87], 'response': [88, 164, 368, 435], 'patients': [94, 148, 168, 283, 320, 395], 'with': [95, 149, 169, 284, 289, 346, 365, 407], 'or': [96, 170, 253], 'without': [97, 171, 321, 450], 'MASI.': [98, 172], 'Methods:': [99], 'conducted': [101], 'proliferation': [102, 195, 350], 'cytotoxity': [104], 'assays': [105], 'compare': [107], 'trametinib': [115], 'human': [123], 'Their': [127], 'vivo': [129, 221, 255], 'tumorigenesis': [130], 'was': [135, 165], 'upon': [138], 'engraftment': [139], 'SCID': [141], 'mice.': [142], 'A': [143], 'series': [145, 393], '179': [147], 'metastatic': [150], 'harboring': [152], 'were': [157], 'analyzed': [158], 'early': [160], 'first': [161], 'line': [162], 'treatment': [163], 'between': [167], 'Results:': [173], 'Our': [174], 'results': [175], 'showed': [176], 'that': [177, 282, 337, 419], 'lines': [184, 191, 243], 'proliferate': [185], 'less': [186], 'rapidly': [187], 'than': [188, 319], 'vitro': [193, 252, 355, 373], '(cell': [194], 'counts': [196], 'after': [197, 229, 235], '7': [198, 227], 'days': [199, 228, 237, 301, 307], 'range': [200], 'from': [201, 211, 260, 269], '3.6': [202], 'x106': [203], '7.7x106': [205], 'cells': [206, 233, 267, 449], 'homozygote': [208], 'cells,': [209], '4.8x104': [212], '5.5x105': [214], 'lines)': [218], '(palpable': [222], 'tumors': [223, 288], 'appeared': [224], 'average': [226], 'inoculation': [230], 'but': [234, 310], '39': [236], 'cells).': [240], 'Heterozygous': [241], 'more': [245, 385, 391], 'resistant': [246], 'either': [250], '(IC50': [256], 'ranged': [259], '0,1': [261], '0,198': [263], 'µM': [264, 273], '8,62': [270], '22,65': [272], 'lines).': [277], 'have': [279, 292, 313], 'shown': [281], 'MASI': [290, 322, 339, 423, 451], 'may': [291], 'initially': [293], 'poorer': [295], 'prognosis': [296], '(median': [297], '733': [300], 'IC95%': [302], '[381;': [303], '1762]': [304], '1011': [306], 'IC95%[879;2969]': [308], 'p=0.236)': [309], 'tend': [311], 'better': [314, 367], 'responses': [315], 'systemic': [317], 'drugs': [318], '(percentage': [323], 'primary': [325], 'resistance': [326], '23%': [327], '34%;': [329], 'p=0.56).': [330], 'In': [331], 'conclusion:': [332], 'This': [333, 359], 'translational': [334], 'shows': [336], 'is': [344, 362], 'associated': [345, 364], 'higher': [348], 'tumorigenic': [352], 'potential': [353], 'vivo.': [358], 'mutational': [360], 'status': [361], 'inhibitor': [371], 'mice': [376], 'xenografts.': [377], 'Clinical': [378], 'relevance': [379], 'these': [381], 'data': [382, 399, 417], 'should': [383], 'be': [384, 456], 'thoroughly': [386], 'larger': [389], 'homogeneous': [392], 'however': [396], 'our': [397, 416], 'preliminary': [398], 'show': [400], 'trend': [402], 'toward': [403], 'clinical-experimental': [405], 'correlation': [406], 'similar': [408], 'yet': [409], 'still': [410], 'statistically': [411], 'insignificant': [412], 'results.': [413], 'If': [414], 'confirmed,': [415], 'suggest': [418], 'mutation': [426], 'could': [427], 'serve': [428], 'as': [429], 'predictive': [431], 'marker': [432], 'patient': [434], 'vemurafenib.': [437, 491], 'The': [438], 'role': [439], 'paradoxical': [441], 'activation': [442], 'MAPK': [445], 'signaling': [446], 'pathway': [447], 'needs': [454], 'further': [457], 'explored.': [458], 'Citation': [459], 'Format:': [460], 'Amelie': [461], 'Boespflug,': [462], 'Luc': [463], 'Thomas,': [464], 'Pascal': [465], 'Rousset,': [466], 'Charles': [467], 'Dumontet,': [468], 'Julie': [469], 'Caramel,': [470], 'Carole': [471], 'Ferraro-Peyret,': [472], 'Pierre': [473], 'Paul': [474], 'Bringuier,': [475], 'Brigitte': [476], 'Balme,': [477], 'Stephane': [478], 'Dalle.': [479], '[abstract].': [492], 'In:': [493], 'Proceedings': [494], '105th': [497], 'Annual': [498], 'Meeting': [499], 'American': [502], 'Association': [503], 'Cancer': [505, 516], 'Research;': [506], '2014': [507], 'Apr': [508], '5-9;': [509], 'San': [510], 'Diego,': [511], 'CA.': [512], 'Philadelphia': [513], '(PA):': [514], 'AACR;': [515], 'Res': [517], '2014;74(19': [518], 'Suppl):Abstract': [519], 'nr': [520], '5602.': [521], 'doi:10.1158/1538-7445.AM2014-5602': [522]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W1484597035', 'counts_by_year': [], 'updated_date': '2024-12-16T05:30:12.607653', 'created_date': '2016-06-24'}